MedinCell (FR0004065605 – MEDCL), a clinical stage pharmaceutical company that develops a portfolio of long-acting injectable products in various therapeutic areas announces today the filing of its 2019/2020 Universal Registration Document (URD) with the French market authority (Autorités des Marchés Financiers, or AMF) under the reference R. 20-015.
The universal registration document notably includes:
• the annual financial report for the year ending on March 31, 2020;
• the management report;
• the CSR report; and
• the report on corporate governance.
This universal registration document may be consulted on the Company’s website (www.medincell.com/), “Investors” section, and on the AMF’s website (www.amf-france.org).
An English version of the document will soon be available on the Company’s website.